| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 6 | | | |
| | | | | 6 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 11 | | | |
| | | | | 12 | | | |
| | | | | 13 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 16 | | | |
| | | | | 17 | | |
| | | | | 17 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 27 | | | |
| | | | | 29 | | | |
| | | | | 32 | | | |
| | | | | 32 | | | |
| | | | | 32 | | | |
| | | | | 32 | | | |
| | | | | 32 | | | |
| | | | | 33 | | | |
| | | | | A-1 | | |
Name
|
| |
Age
|
| |
Position
|
| |
Director
Since |
|
Lindsay A. Rosenwald, M.D. | | |
69
|
| |
Executive Chairman of the Board of Directors
|
| |
2014
|
|
Claude Maraoui | | |
58
|
| | President, Chief Executive Officer & Director | | |
2016
|
|
Neil Herskowitz | | |
67
|
| | Director | | |
2021
|
|
Justin Smith | | |
50
|
| | Director | | |
2021
|
|
Miranda Toledano | | |
47
|
| | Director | | |
2021
|
|
Board Diversity Matrix (As of April 24, 2024)
|
| ||||||||||||||||||
Total Number of Directors
|
| |
5
|
| |||||||||||||||
| | |
Female
|
| |
Male
|
| |
Non-Binary
|
| |
Did not
disclose Gender |
| ||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | |
Directors
|
| | | | 1 | | | | | | 4 | | | | | | | | |
Part II: Demographic Background | | | | | | | | | | | | | | | | | | | |
White
|
| | | | 1 | | | | | | 2 | | | | | | | | |
Did Not Disclose Demographic Background
|
| |
2
|
| | | | | | |
Board Diversity Matrix (As of April 28, 2023)
|
| ||||||||||||||||||
Total Number of Directors
|
| |
6
|
| |||||||||||||||
| | |
Female
|
| |
Male
|
| |
Non-Binary
|
| |
Did not
disclose Gender |
| ||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | |
Directors
|
| | | | 1 | | | | | | 5 | | | | | | | | |
Part II: Demographic Background | | | | | | | | | | | | | | | | | | | |
White
|
| | | | 1 | | | | | | 3 | | | | | | | | |
Did Not Disclose Demographic Background
|
| |
2
|
| | | | | | |
| | |
2023
|
| |
2022
|
| ||||||
Audit Fees
|
| | | $ | 890,300 | | | | | $ | 693,200 | | |
Audit-Related Fees
|
| | | | — | | | | | | — | | |
Tax Fees
|
| | | | — | | | | | | 56,900 | | |
All Other Fees
|
| | | | — | | | | | | — | | |
Total Fees
|
| | | $ | 890,300 | | | | | $ | 750,100 | | |
Name
|
| |
Age
|
| |
Position
|
|
Claude Maraoui | | |
58
|
| | President, Chief Executive Officer and Director | |
Joseph Benesch | | |
57
|
| | Chief Financial Officer and Corporate Controller | |
Name and principal position
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
($) |
| |
Stock
Awards ($) |
| |
Nonequity
Plan Compensation ($)(2) |
| |
All Other
Compensation ($)(3) |
| |
Total
($) |
| |||||||||||||||||||||
Claude Maraoui
Chief Executive Officer |
| | | | 2023 | | | | | $ | 550,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 371,250 | | | | | $ | 13,200 | | | | | $ | 934,450 | | |
| | | 2022 | | | | | $ | 473,900 | | | | | $ | — | | | | | $ | 1,053,000 | | | | | $ | 334,200 | | | | | $ | 12,200 | | | | | $ | 1,873,300 | | | ||
Joseph Benesch
Chief Financial Officer |
| | | | 2023 | | | | | $ | 300,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 103,200 | | | | | $ | 5,835 | | | | | $ | 409,035 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
Ernie De Paolantonio
Former Chief Financial Officer |
| | | | 2023 | | | | | $ | 31,693(1) | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | 1,269 | | | | | $ | 32,962 | | |
| | | 2022 | | | | | $ | 306,800 | | | | | $ | — | | | | | $ | 1,139,700 | | | | | $ | — | | | | | $ | 12,200 | | | | | $ | 1,458,700 | | |
| | | | | | | | |
Options Awards
|
| | |
Stock or RSU Awards
|
| ||||||||||||||||||||||||||||||
Name
|
| |
Grant
Date |
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| | |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market Value
of Shares or Units of Stock That Have Not Vested ($)(1) |
| |||||||||||||||||||||
Claude Maraoui
|
| | | | 10/19/2015 | | | | | | 1,250,000 | | | | | | — | | | | | $ | 0.065 | | | | | | 10/19/2025 | | | | | | | — | | | | | $ | — | | |
| | | | | 9/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | 59,300(2) | | | | | $ | 341,568 | | |
| | | | | 12/10/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | 88,506(3) | | | | | $ | 509,795 | | |
| | | | | 7/21/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | 225,000(4) | | | | | $ | 1,296,000 | | |
Joseph Benesch
|
| | | | 7/1/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | 6,667(5) | | | | | $ | 38,402 | | |
| | | | | 7/21/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 37,500(4) | | | | | $ | 216,000 | | |
Plan Category
|
| |
Number of
Securities to Be Issued upon Exercise of Outstanding Options, Warrants and Rights (#)(1) |
| |
Weighted
Average Exercise Price of Outstanding Options, Warrants and Rights ($)(2) |
| |
Number of
Securities Remaining Available for Future Issuance under Equity Compensation Plans Excluding Securities Reflected in Column (a)(3) |
| |||||||||
| | |
(a)
|
| |
(b)
|
| |
(c)
|
| |||||||||
Equity compensation plans approved by security
holders: |
| | | | 4,076,792 | | | | | $ | 1.49 | | | | | | 1,487,994 | | |
Equity compensation plans not approved by security holders:
|
| | | | — | | | | | $ | — | | | | | | — | | |
Total:
|
| | | | 4,076,792 | | | | | $ | 1.49 | | | | | | 1,487,994 | | |
Name
|
| |
Fees Earned
in Cash ($)(1) |
| |
Stock
Awards ($)(2) |
| |
Total ($)
|
| |||||||||
Lindsay A. Rosenwald, M.D.(3)
|
| | | $ | 50,000 | | | | | $ | — | | | | | $ | 50,000 | | |
Neil Herskowitz(3)
|
| | | $ | 60,000 | | | | | $ | 50,000 | | | | | $ | 110,000 | | |
Jeffrey Paley, M.D(4)
|
| | | $ | 50,000 | | | | | $ | 50,000 | | | | | $ | 100,000 | | |
Justin Smith(3)
|
| | | $ | 50,000 | | | | | $ | 50,000 | | | | | $ | 100,000 | | |
Miranda Toledano(3)
|
| | | $ | 50,000 | | | | | $ | 50,000 | | | | | $ | 100,000 | | |
Name and Address of Beneficial Owner
|
| |
Number of
Shares of Common Stock Beneficially Owned |
| |
Percentage of
Common Stock |
| ||||||
Five percent or more beneficial owners | | | | | | | | | | | | | |
Fortress Biotech, Inc.(1)
|
| | | | 9,860,467 | | | | | | 49.37% | | |
Named Executive Officers and Directors | | | | | | | | | | | | | |
Lindsay A. Rosenwald, M.D.(2)
|
| | | | 820,715 | | | | | | 4.11% | | |
Claude Maraoui(3)
|
| | | | 1,790,624 | | | | | | 8.44% | | |
Neil Herskowitz
|
| | | | 34,245 | | | | | | * | | |
Justin Smith
|
| | | | 97,245 | | | | | | * | | |
Miranda Toledano
|
| | | | 34,245 | | | | | | * | | |
Joseph Benesch
|
| | | | 16,543 | | | | | | * | | |
All executive officers and directors as a group (6 persons)
|
| | | | 2,793,617 | | | | | | 13.16% | | |
]Z"JAK32VD++2KJ=/+IEU$L.&729]6: UQ2EW(EYQ
M10Z52(.R49D3G('%*0,5;]QA"2RFE-0W:P7EC]T5CC"77D"H2#),RH @"4;9
M=$\X;_ J4.'
MR;+'EFI!?B)R_!&/\_DV=^4X+3(X#&)_G\FS<>2""TC"0A_G\FS6<&9T[,N$
M7@\NSGRD5C1V#NB\/DV<[O+J <$_-'=#A\FR ;L>G\!E#4T
M3L_R5^852ZP_+XX&AB?Y)9CBJ?8_\L35?U!7\C^)XRN 1'DXI84L6VM..(3[J\NJ<>>7'FNEJ@T&LVDJ6;>TEZ'M-*3ZJT\ID,
M3OV7+GCRWJ;USC_(+V;%)R, B=ZW#[AD1J5HE/0BZF8#0S*#FTQ^DE-QI4F#%]XG;0*"R] XX2E(]&HENFP
M:S)"5;D;TD2S\3+0P%.R;)+"77S\GA2LA11MX^Q884NK2\:7);3;KKQ3^AI-
MXE(0E:99]O9K^-O 7//+VU1Q%*R".X]!MGH,.0LX)F3Z%R%L]Q#)GUW&2E)3
M[=0%8N3S*)Q]F;C5A:4D*0_$9Q>99.DY;Q"?<99>=4HE+5VR<49MI<4:]-?
MC3H&/-\]OIF(5\&MEJJLF:4N5D3\CS370(]N2VO-YL
MPHIPQWXQH4KDOJ)C1SMQ9K0.&M3AIU&6Q9,ML!7=;U=->-2&O2V)D&1!'5 8
M)8+1ZCN$8!&50F(!I!^2 00PHEM\R97YQV1J)96KE]K6HT; ,;89G4U;;0;G#,H:W3UE<4M4")NC $0S6CUITSJL.!+B5YCL&,,S&
MJ%=(XA\T=:WEK$[2K 2\L,S"3&J6H?7P:1DKP0*PVU
M9V;>WI=&GE4139]537&\4M%3O$FC4&CFPQ& WQIB5FY@4RQR]MC:W$S2VVB:=I*
MF??$1Y-(5B;KH]5F9<#-0D$)2<,W:8#7[[-RL56[1NT*U<51'V:24'';,"6^
M"3=1,Y25_L[:TI73<58;&=)D
9?C.&S):6P\G3I886]/\ 2U#[O^[MO3-FPUMI4A)I6HE$9DDBT(C!
M-<3M4:E[M=!:,L[&
M^0;*'"@S:M]UFO2I$51I3W"0L_!2M>I%[!!;N*<;O:6YFOVL!V*RY&V(<<(B
M(U=Q)Z>/P!JXZT,J
M .1?:B_T#S?]#:_M+(#^;..
HZB/,LD6%360G94A3+.ZW:><4\[M0
MH]K7:^*G4U>!: +)E^0VV-8_'GPX+-EQ]V%ND=GMO.+3
MHCY1/=0G